Skip to main contentSkip to navigationSkip to search
ENZY  
SEK  %
Logotype
ENZY  
SEK  %
Logotype

Investors

Financial reports

2024

November 7, 2024
Interim report Q3/2024: Focus on developing existing and new markets
July 18, 2024
Interim report Q2/2024: Enzymatica builds momentum for expansion
April 25, 2024
Interim report Q1/2024: MDR certification opens up great commercial opportunities
April 9, 2024
Enzymatica publishes annual report for 2023
February 16, 2024
Year-end report 2023: Scientific and regulatory progress generating international interest

2023

November 7, 2023
Interim report Q3/2023: Research results that reshape the competitive landscape
July 18, 2023
Interim report Q2/2023: An exciting and important time ahead
April 27, 2023
Interim report Q1/2023: Strong start to the year – Enzymatica’s growth journey continues according to plan
April 5, 2023
Enzymatica publishes annual report for 2022
February 17, 2023
Interim report Q4/2022: A year that laid the foundation for growth

2022

November 2, 2022
Interim report Q3/2022: A broader role for ColdZyme adds potential for the future
July 19, 2022
Interim report Q2/2022: Improved sales give confidence for the future
April 28, 2022
Interim report Q1/2022: Our financial targets remain in place
March 31, 2022
Enzymatica publishes annual report for 2021
February 17, 2022
Year-end report: Clear signs of favourable market trends after a challenging 2021

2021

November 2, 2021
The long-term plan remains in challenging times
July 16, 2021
Continued lower sales due to pandemic but some stabilization
April 29, 2021
Lower sales due to the pandemic but new rights issue secures continued international expansion
March 31, 2021
Enzymatica Publication of the Annual Report 2020
February 18, 2021
Positive operating result and almost doubled sales for the fourth quarter

2020

November 3, 2020
Continued strong sales increase and positive cash flow in third quarter
July 16, 2020
Doubled sales also during the second quarter
May 5, 2020
Doubled sales and positive earnings for the first quarter
February 13, 2020
ColdZyme – third largest cold brand in Sweden

2019

November 5, 2019
Very strong increase of sales during the third quarter
July 17, 2019
Good growth in Q2, driven mainly by strong sales in Sweden
May 7, 2019
Continued strong growth in Sweden, but lower total sales during the quarter
February 19, 2019
Enzymatica AB: Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany

2018

October 31, 2018
Enzymatica AB: Breakthrough agreement for Japan and lower sales in Q3 due to restrictions in Germany
July 17, 2018
Enzymatica AB: Lower sales in Q2 but 31% increase for the first half of the year
April 26, 2018
Enzymatica AB: Continued growth during the first quarter
March 28, 2018
Enzymatica AB: Enzymatica - publication of the annual report 2017
February 14, 2018
Enzymatica AB: Strong growth and international breakthrough in 2017

2017

November 1, 2017
Enzymatica AB: Interim report for Enzymatica AB (publ) January-September 2017
July 20, 2017
Enzymatica AB: Continued sales growth and breakthrough order from STADA
April 20, 2017
Enzymatica AB: Breakthrough in Germany and continued increase in sales
April 6, 2017
Enzymatica AB: Enzymatica - publication of the annual report 2016
February 16, 2017
Enzymatica AB: Geographic expansion and continued growth in 2016

2016

July 18, 2016
Enzymatica AB: Excellent volume growth for ColdZyme®
April 20, 2016
Enzymatica - publication of the annual report 2015
April 18, 2016
Interim Report for Enzymatica AB (publ) January-March 2016

2014

May 5, 2014
Enzymatica’s 2013 Annual Report now available